(Total Views: 476)
Posted On: 05/15/2025 1:36:04 AM
Post# of 154696
From past trial protocol:
Outcome Measures:
Correlation between CCR5 expression (CTCs, CAMLs) and PD- L1 expression.
https://clinicaltrials.gov/study/NCT03838367?...amp;rank=1
Last press release: ".....found that leronlimab treatment correlated with increased expression of an immune cell protein or “checkpoint inhibitor” known as programmed death-ligand 1 (“PD-L1”) on patient’s circulating tumor cells (“CTCs”). "
PD-L1 was no surprise for Dr. J.
He knew back then Cytodyn was hunting for the correlation.
Today & forward has been long in the making.....
Outcome Measures:
Correlation between CCR5 expression (CTCs, CAMLs) and PD- L1 expression.
https://clinicaltrials.gov/study/NCT03838367?...amp;rank=1
Last press release: ".....found that leronlimab treatment correlated with increased expression of an immune cell protein or “checkpoint inhibitor” known as programmed death-ligand 1 (“PD-L1”) on patient’s circulating tumor cells (“CTCs”). "
PD-L1 was no surprise for Dr. J.
He knew back then Cytodyn was hunting for the correlation.
Today & forward has been long in the making.....
(6)
(0)
